Andrew Forman's practice involves counseling clients in a wide range of antitrust matters, with a specific focus on mergers and acquisitions, joint ventures, and representing clients in connection with investigations by the U.S. Department of Justice and the Federal Trade Commission (FTC). Andy also has experience in private antitrust litigation, including antitrust class action litigation. He has represented clients in matters involving a variety of industries, including the pharmaceutical, medical device, airline, automobile, software, semiconductor, industrial and engineered products, and consumer products industries. Among the clients Andy has represented are Eli Lilly, Salix, Anheuser-Busch InBev, US Airways, Pfizer, Microsoft, and Goodyear.
Recognized as a leading antitrust lawyer, Andy has helped lead the Cadwalader teams that have won the last two Global Competition Review antitrust Matter of the Year awards, in 2015 for work with Eli Lilly & Company in connection with its acquisition of Novartis Animal Health and in 2014 for work in connection with the US Airways/American Airlines merger. He also was recommended in The Legal 500 (2012 -2013) for his work in merger clearances and was part of the team accepting Benchmark Litigation's award for 2013 U.S. Antitrust Group of the Year and for a national Impact Case of the Year awardfor the US Airways/American merger clearance.
Prior to joining Cadwalader, Andy worked for the FTC's Bureau of Competition (Mergers I), where he helped lead antitrust investigations in large mergers and acquisitions in the pharmaceutical, medical device, consumer products, industrial products, and aircraft components industries.
Andy received his J.D., cum laude, from Georgetown University and his undergraduate degree as an Honors Graduate from Washington University in St. Louis. Following law school, he served as a judicial law clerk for the D.C. Court of Appeals. He is admitted to the bar in the District of Columbia and Maryland.
Antitrust representations include:
•Salix Pharmaceuticals, Ltd. in its $15.6 billion acquisition by Valeant Pharmaceuticals International, Inc.
•Eli Lilly & Company in connection with its $5.4 billion acquisition of Novartis Animal Health.
•Acorda Therapeutics, Inc. in its pending acquisition of Civitas Therapeutics, Inc.
•Salix Pharmaceuticals in connection with its proposed transaction with Cosmo Technologies.
•US Airways in its $17 billion merger with American Airlines.
•Vertis Holdings, Inc., an advertising and direct mail company, in connection with its bankruptcy sale to rival Quad/Graphics, Inc.
•US Airways in its slot transaction with Delta Air Lines.
•Pfizer Inc. in its $68 billion acquisition of Wyeth Pharmaceuticals.
•Microsoft Corporation in numerous antitrust matters.
•Elan Corporation PLC in the $3.3 billion sale of its multiple sclerosis joint venture interest to Biogen Idec, Inc.
•Anheuser-Busch InBev in various antitrust matters.
•Goodyear Tire & Rubber Company in various antitrust matters.
•Cadwalader Represents Towers Watson in its Acquisition of Acclaris, a Healthcare Technology Provider May 11, 2015
•New Deals - Lawyers on Major Transactions Jan 29, 2009
•Cadwalader's Antitrust Group Wins 2015 Global Competition Review Matter of the Year Award Apr 15, 2015
Clients & Friends Memos
•Recent Court and Agency Actions Suggest Increased Antitrust Risk Over Disgorgement, Particularly in the Pharmaceutical Industry May 05, 2015
•6 Steps for Quick FTC Antitrust Clearance of Pharma Mergers May 01, 2015
•So The Agency Wants to Talk: Advice and Issues in Pre-Complaint Depositions Mar 16, 2015
Senior Judges' Chambers
District of Columbia Court of Appeals